Reviewing Subsector Performance over the Last 12 Months: Healthcare Spread Performance, LTM subsector spread levels compared to JULI ex EM

研报英文原文证据摘录

Reviewing Subsector Performance over the Last 12 Months: Healthcare Spread Performance, LTM subsector spread levels compared to JULI ex EM

Pipeline Development for Pharma Companies

Recent Clinical Data Releases Upcoming Pipeline Catalysts

Company Product Recent Data Points Direction Company Product Event Time Period

Skyrizi IBD ramp / Ph2 CD data 2026+ ABBV N/A No recent material developments

ABBV Aesthetics Recovery dynamics 2026+

Amylin Ph2 trial / Ph1b data (obesity) 2H26

AMGN N/A No recent material developments

Prolio/Xgeva Biosimilar erosion dynamics 2026

Ph2 did not meet endpoints / continuing Maritide Ph3 details 2026/27

BIIB diranersen AMGN

development given signs of benefit Uplizna gMG Ramp 2026+

Dazodalibep Ph3 data 2H26

BMY N/A No recent material developments

Leqembi Uptake / Ramp 2026+

Skyclarys Uptake / Ramp 2026+

GILD N/A No recent material developments BIIB

litifilimab Tw o Ph3 studies 2H26

HD Spinraza Uptake / Ramp 2026+

JNJ N/A No recent material developments

SubQ Opdivo Ramp 2026+

Zepbound CVS restoring coverage Cobenfy Ph3 Data 2H26/1H27 LLY BMY

Foundayo FDA approval Milvexian Ph3 data 2H26

CELMoD Ph3 2L+MM Data 2026/27

MRK N/A No recent material developments Lenacapavir & combos Launch dynamics / updates 2026+

GILD Anito-cel Launch 2H26

Sigvotatug Vedotin Ph3 trial failure in 2L+ NSCLC Livdelzi PBC launch dynamics 2026+ PFE

PF’3944 (Obesity) Ph2b met endpoint / mixed vs peers Tremfya IBD ramp 2026+

Inlexzo Ramp in NMIBC 2026+

Source: Company reports and JPMe JNJ

Tecvayli & combo Ramp / approval / indication 2026+

Carvykti Ph3 Data 2026/27

Tirzepitide Ex-US trends/ramp 2026+

LLY Kisunla Ph3 preclinical Alz data 2027

Eloralintide Ph2 data (combo w / tirzepitide) 2H26

enlicitide FDA approval 2H26

MRK Winrevair Uptake trends / Ph2 data (PH) 2026+